-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Neutral on Abivax, Raises Price Target to $110

Benzinga·06/30/2026 12:53:03
Listen to the news
Wedbush analyst David Nierengarten maintains Abivax (NASDAQ:ABVX) with a Neutral and raises the price target from $90 to $110.